Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price

TriSalus Life Sciences (NASDAQ:TLSI) had its price objective decreased by Canaccord Genuity Group from $12.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 53.51% from the stock’s current price.

A number of other research analysts have also recently issued reports on TLSI. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Finally, Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.00.

TriSalus Life Sciences Stock Down 4.4%

NASDAQ:TLSI traded down $0.21 on Friday, hitting $4.56. The stock had a trading volume of 631,979 shares, compared to its average volume of 171,258. TriSalus Life Sciences has a 52 week low of $3.42 and a 52 week high of $7.95. The business’s fifty day moving average is $5.41 and its 200 day moving average is $5.36. The company has a market cap of $228.27 million, a PE ratio of -2.26 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. Equities analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of TLSI. Bank of America Corp DE grew its stake in shares of TriSalus Life Sciences by 1.8% during the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after acquiring an additional 3,374 shares during the period. Connective Capital Management LLC boosted its position in TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock worth $179,000 after purchasing an additional 3,717 shares during the period. Millennium Management LLC increased its stake in shares of TriSalus Life Sciences by 17.7% in the third quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after purchasing an additional 5,359 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of TriSalus Life Sciences in the second quarter valued at approximately $29,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reaffirmed 2026 revenue guidance of $60.0–$62.0 million and said it is expanding its PEDD portfolio, signaling confidence in top-line growth that is above street consensus. TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
• Positive Sentiment: Q4 results slightly beat expectations: EPS of ($0.12) vs. consensus ($0.13) and revenue of $13.21M vs. ~$13.20M — a modest upside that supports management’s guidance but leaves limited upside surprise. TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and …
• Positive Sentiment: Equity research support: Lake Street reiterated a Buy rating, which can bolster investor confidence following the results and guidance. Lake Street Sticks to Its Buy Rating for TriSalus Life Sciences (TLSI)
• Neutral Sentiment: Management commentary and the full earnings call/transcript provide detail on execution and the PEDD rollout; useful for assessing cadence but largely reiterates the press release. TriSalus (TLSI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst note: Northland Securities published FY2025 estimates — a data point for modelers but not a clear directional catalyst on its own. Northland Securities Estimates TLSI FY2025 Earnings
• Negative Sentiment: Market/technical headwinds: the stock traded heavily on the news and is trading below its 50- and 200-day moving averages — a setup that can amplify near-term selling as some traders react to momentum and valuation concerns.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.